In mouse models of hepatic fibrosis, either targeted deletion or pharmacological inhibition of CCR2 or CCR5 resulted in lower immune-cell activation and reduced liver fibrosis [134, 135]. Here, CCR5 is linked to Hepatic fibrosis.